Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    4D Molecular Therapeutics...

    NASDAQ: FDMT · Real-Time Price · USD
    4.38
    -0.01 (-0.23%)
    At close: Jun 16, 2025, 3:59 PM
    4.29
    -2.05%
    Pre-market: Jun 17, 2025, 07:48 AM EDT

    4D Molecular Therapeutics Statistics

    Share Statistics

    4D Molecular Therapeutics has 46.32M shares outstanding. The number of shares has increased by -10.45% in one year.

    Shares Outstanding

    n/a
    		 46.32M

    Shares Change (YoY)

    n/a
    		 -10.45%

    Shares Change (QoQ)

    n/a
    		 0.16%

    Owned by Institutions (%)

    n/a
    		 84.32%

    Shares Floating

    n/a
    		 41.55M

    Failed to Deliver (FTD) Shares

    n/a
    		 3,720

    FTD / Avg. Volume

    n/a
    		 0.61%

    Short Selling Information

    The latest short interest is 4.35M, so 9.4% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 4.35M

    Short % of Shares Out

    n/a
    		 9.4%

    Short % of Float

    n/a
    		 9.78%

    Short Ratio (days to cover)

    n/a
    		 10.97

    Valuation Ratios

    The PE ratio is -1.87 and the forward PE ratio is -1.14. 4D Molecular Therapeutics's PEG ratio is -0.12.

    PE Ratio

    n/a
    		 -1.87

    Forward PE

    n/a
    		 -1.14

    PS Ratio

    n/a
    		 8120.72

    Forward PS

    n/a
    		 1.9

    PB Ratio

    n/a
    		 0.59

    P/FCF Ratio

    n/a
    		 -2.17

    PEG Ratio

    n/a
    		 -0.12
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for 4D Molecular Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 14.92, with a Debt / Equity ratio of 0.05.

    Current Ratio

    n/a
    		 14.92

    Quick Ratio

    n/a
    		 14.92

    Debt / Equity

    n/a
    		 0.05

    Debt / EBITDA

    n/a
    		 -0.13

    Debt / FCF

    n/a
    		 -0.18

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $163

    Profits Per Employee

    n/a
    		 $-708,669.6

    Employee Count

    n/a
    		 227

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -81.6% in the last 52 weeks. The beta is 2.83, so 4D Molecular Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.83

    52-Week Price Change

    n/a
    		 -81.6%

    50-Day Moving Average

    n/a
    		 3.46

    200-Day Moving Average

    n/a
    		 6.47

    Relative Strength Index (RSI)

    n/a
    		 60.78

    Average Volume (20 Days)

    n/a
    		 608,984

    Income Statement

    In the last 12 months, 4D Molecular Therapeutics had revenue of 37K and earned -160.87M in profits. Earnings per share was -2.98.

    Revenue

    n/a
    		 37K

    Gross Profit

    n/a
    		 37K

    Operating Income

    n/a
    		 -187.84M

    Net Income

    n/a
    		 -160.87M

    EBITDA

    n/a
    		 -187.84M

    EBIT

    n/a
    		 -187.84M

    Earnings Per Share (EPS)

    n/a
    		 -2.98
    Full Income Statement

    Balance Sheet

    The company has 149.34M in cash and 24.61M in debt, giving a net cash position of 124.73M.

    Cash & Cash Equivalents

    n/a
    		 149.34M

    Total Debt

    n/a
    		 24.61M

    Net Cash

    n/a
    		 124.73M

    Retained Earnings

    n/a
    		 -576.2M

    Total Assets

    n/a
    		 515.73M

    Working Capital

    n/a
    		 305.67M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -134.59M and capital expenditures -3.79M, giving a free cash flow of -138.37M.

    Operating Cash Flow

    n/a
    		 -134.59M

    Capital Expenditures

    n/a
    		 -3.79M

    Free Cash Flow

    n/a
    		 -138.37M

    FCF Per Share

    n/a
    		 -2.57
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -507678.38% and -434778.38%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -507678.38%

    Pretax Margin

    n/a
    		 -434778.38%

    Profit Margin

    n/a
    		 -434778.38%

    EBITDA Margin

    n/a
    		 -507678.38%

    EBIT Margin

    n/a
    		 -507678.38%

    FCF Margin

    n/a
    		 -373975.68%

    Dividends & Yields

    FDMT does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for FDMT is $37, which is 744.7% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $37

    Price Target Difference

    n/a
    		 744.7%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 10
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -0.19

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist